Associations between fatty acid composition in serum cholesteryl esters and liver fat, basal fat oxidation, and resting energy expenditure: a population-based study

Michael Fridén,1 Fredrik Rosqvist,1 Joel Kullberg,2,3 Håkan Ahlström,2,3 Lars Lind,4 and Ulf Risérus1

1Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden; 2Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden; 3Antaros Medical AB, BioVenture Hub, Mölndal, Sweden; and 4Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala, Sweden

ABSTRACT

Background: We have repeatedly shown in short-term feeding trials that a high intake of dietary n–6 PUFAs, i.e. linoleic acid, prevents liver fat accumulation compared with saturated fat. However, population-based data is lacking and the mechanisms behind such effects are unclear.

Objective: To investigate associations between serum cholesteryl ester (CE) fatty acids and liver fat, basal fat oxidation [respiratory quotient (RQ)], and resting energy expenditure (REE). We hypothesized that PUFA in particular is inversely associated with liver fat and that such a relation is partly explained by a PUFA-induced increase in basal fat oxidation or REE.

Methods: Cross-sectional analyses using linear regression models in a population-based cohort with data on serum CE fatty acid composition and liver fat (n = 308).

Results: Linoleic acid (18:2n–6) (β = −0.03, 95% CI: −0.06, −0.001) and Δ5 desaturase index were inversely associated, whereas, γ-linolenic acid (18:3n–6) (β = 0.59, 95% CI: 0.28, 0.90), dihomo-γ-linolenic acid (20:3n–6) (β = 1.20, 95% CI: 0.65, 1.75), arachidonic acid (20:4n–6) (β = 0.08, 95% CI: 0.002, 0.16), palmitoleic acid (16:1n–7) (β = 0.37, 95% CI: 0.04, 0.70), Δ6 desaturase, and stearoyl CoA desaturase-1 (SCD-1) index were directly associated with liver fat after adjustment for confounders. Several serum CE fatty acids were correlated with both liver fat and REE, but only the association between DHA (22:6n–3) and liver fat was clearly attenuated after adjustment for REE (from β = −0.63 95% CI: −1.24, −0.02 to β = −0.34, 95% CI: −0.95, 0.27). Palmitoleic acid and SCD-1 were weakly inversely correlated with RQ but could not explain a lower liver fat content.

Conclusions: Several serum CE fatty acids are associated with liver fat, among them linoleic acid. Although we identified novel associations between individual fatty acids and RQ and REE, our findings imply that PUFAs might prevent liver fat accumulation through mechanisms other than enhanced whole-body energy metabolism.

Keywords: fatty acid composition, cholesteryl esters, liver fat, energy expenditure, fat oxidation, respiratory quotient

Introduction

Accumulation of fat in the liver (hepatic steatosis) is the key disorder in nonalcoholic fatty liver disease (NAFLD), which is strongly associated with increased risk of cardiometabolic diseases (1–3). Excessive energy intake is the main driver of steatosis, but accumulating evidence suggest that also the composition of fat and carbohydrate could play a major role (4). A higher total dietary fat content has been associated with hepatic steatosis (5, 6), although the quality of fat consumed, as indicated by randomized controlled feeding trials, may play a partial role in these observations (7–10). When matched for calories (7–10) and macronutrient composition (8, 10), PUFAs and MUFAs seem to counteract an increase in liver fat compared with SFAs. However, the mechanisms underlying these effects remain unclear. In contrast to SFA, postprandial oxidation rates of isotope-labeled PUFAs and MUFAs have generally been shown to be higher in both humans and rats (11–14), possibly explaining the favorable effects of certain unsaturated fatty acids. Altered substrate metabolism by unsaturated fats are supported by smaller human...
trials using indirect calorimetry (15–18), although conflicting results have been reported (19, 20). Furthermore, PUFAs tend to
downregulate the transcription of genes involved in lipogenesis
and upregulate genes involved in β-oxidation and thermogenesis
(21). Isoacoric studies in rodents have also shown that PUFAs
and MUFAs decrease body fat and ectopic fat deposition
compared with SFA while increasing energy expenditure (22–
24). Other studies have, however, failed to detect an effect on the
latter (25). Findings from rodent models on the impact of fatty
acids on energy expenditure are partly supported by longer-term
human trials (17, 26, 27), whereas others have failed to show an
effect (19, 20, 27). Consequently, although controversy remains,
a higher fat oxidation rate and increased energy expenditure may
provide plausible mechanisms behind the favorable impact of
PUFAs on liver fat accumulation. However, since self-reported
recall data of fatty acid composition have several limitations, we
aimed to design a study that investigated these associations in a
population-based study using serum fatty acid biomarkers, which
partly reflect dietary fatty acids (28–30), but also endogenous
pathways of fat metabolism which may be important for liver fat
accumulation and the development of NAFLD. Such a study is, to
our knowledge, lacking but needed to provide novel information
regarding the links between fatty acids, liver fat content, and
energy metabolism on a population level.

Here, we investigated the associations between fatty acids
measured in serum cholesteryl esters (CEs) and liver fat content,
basal fat oxidation [assessed as respiratory quotient (RQ)], and
resting energy expenditure (REE). Further, we examined whether
potential associations between fatty acids and liver fat might be
mediated by altered energy metabolism.

Methods
Subjects
This cross-sectional study is based on baseline data of the
population-based POEM (Prospective investigation of Obesity,
Energy and Metabolism) cohort, initiated in Uppsala, Sweden,
in 2010, with the aim of studying the pathophysiological
links between obesity and vascular dysfunction and future
cardiovascular disorders (31). Participants were recruited in a
random order by mail 1 mo after their 50th birthday between
October 2010 and October 2016 from an official registry of
inhabitants in Uppsala. A total of 502 males and females agreed
to participate (25%). Of these, fatty acid composition data in
serum CEs were obtained from 500 subjects, basal RQ from
483 subjects, REE normalized for fat-free mass (REE/FFM)
from 480 subjects, and liver fat content were obtained from
310 subjects. Data on liver fat content and fatty acid composition
were available for 308 subjects (Figure 1). All participants gave
their written informed consent. The study was approved by the
Ethics Committee of Uppsala University and conformed to the
ethical guidelines of the Declaration of Helsinki.

FIGURE 1 Flow chart of the POEM study.
Blood samples and anthropometric measurements were taken in the morning after an overnight fast. Blood samples were collected on the same day as the indirect calorimetry measurements, however, liver fat assessment using MRI was not performed until a couple of weeks later. Height and weight were recorded and waist circumference (WC) was measured at the umbilical level. BMI was calculated as the weight in kilograms divided by the height in meters squared (kg/m²). Total serum cholesterol, LDL cholesterol, HDL cholesterol, triglycerides (TG), fasting plasma glucose, and fasting insulin concentrations were assessed by standard laboratory techniques at Uppsala University Hospital. All participants completed a comprehensive lifestyle questionnaire regarding diet, alcohol intake, and smoking habits, among others.

**Serum CE fatty acid composition**

Fatty acid composition in serum CEs was measured using GC (Agilent Technologies system, 6890 N) as previously described (32). A total of 13 fatty acids (14:0–22:6n–3) were measured and individually presented as the proportion of total fatty acids in serum CEs (Table 1). Stearoyl CoA desaturase-1 (SCD-1), Δ5 desaturase (D5D), and Δ6 desaturase (D6D) were estimated using the product-to-precursor ratio of 16:1n–7/16:0, 20:4n–6/20:3n–6, and 18:3n–6/18:2n–6, respectively.

Intake of dietary fatty acids are partly reflected in serum CE, with generally stronger correlations shown for linoleic acid [Spearman’s rho: 0.34 (P < 0.001)] and DHA [Spearman’s rho: 0.38 (P < 0.001)] than for even-chain SFAs such as palmitic acid [Spearman’s rho: 0.26 (P < 0.001)] and stearic acid [Spearman’s rho: 0.07 (P = 0.27)] (28). Furthermore, fatty acids measured in circulating CE have demonstrated strong correlations with fatty acids measured in circulating phospholipids in previous population-based observational and interventional studies from Sweden (33).

As a potential surrogate marker for adipose tissue fatty acid composition and possible long-term reflection of dietary intake, 9 nonesterified fatty acids (NEFA) (14:0–22:6n–3) were measured using the same procedure as for fatty acids in serum CE (i.e. separation using thin-layer chromatography and profiled using GC). Although fatty acids measured in serum CE reflect dietary intake over a couple of days to weeks, NEFA through the slower turnover rate of adipose tissue might reflect dietary intake over several months. NEFA in serum were therefore included as exploratory exposure variables in post hoc analyses.

**Liver fat**

Liver fat content was assessed using MRI. All subjects were imaged on a 1.5T clinical MRI system (Achieva, Philips Healthcare) in a supine position using the body coil and 1 dedicated water-fat MRI scan in 1 breath hold. Liver MRI scan parameters were: repetition time (TR)/echo time 1 (TE1)/ΔTE = 8.66/0.92/1.32 ms, 6 unipolar echoes, flip angle 5 degrees. Imaged field of view (FOV) was 384 × 288 × 150 mm³, and reconstructed voxel size was 3.0 × 3.0 × 10.0 mm³. Water-fat image reconstruction was performed using an in-house developed algorithm. Liver fat concentrations were quantified using manual delineation of as large a volume of interest as possible (from the entire liver) avoiding tissue borders and large vessels and

| TABLE 1 | Population characteristics (n = 308)² |
|----------|-------------------------------------|
|          | All participants (n = 308)           |
| Females/males, % | 51/49                               |
| University education, % | 49                                  |
| Current smokers, % | 7.5                                 |
| VO₂max, L/min | 2.36 ± 0.68                         |
| Anthropometrics |                                     |
| Weight, kg   | 80.1 ± 15.2                         |
| BMI, kg/m²   | 25.8 (4.9)                          |
| WC, cm       | 93 ± 11                             |
| Energy metabolism² |                                   |
| REE, kcal   | 1409.1 ± 248.8                      |
| REE/FFM, kcal/kg FFM | 28.6 ± 6.6                        |
| RQ          | 0.78 ± 0.06                         |
| Body composition |                                       |
| BF, %       | 27.8 ± 8.7                          |
| FFM, kg     | 52.3 ± 16.4                         |
| Liver fat, % | 2.1 (3.7)                           |
| NAFLD prevalence, % | 22.7                                |
| Glucose metabolism |                                      |
| Fasting plasma insulin, mU/L | 3.6 (3.6)                          |
| Fasting plasma glucose, mmol/L | 5.0 (0.6)                        |
| Lipids      |                                      |
| Total serum cholesterol, mmol/L | 5.3 ± 1.0                          |
| HDL cholesterol, mmol/L | 1.4 (0.4)                         |
| LDL cholesterol, mmol/L | 3.4 ± 0.9                          |
| TG, mmol/L  | 1.0 (0.7)                           |
| Serum cholesterol ester fatty acids³ |                                 |
| Myristic acid 14:0, % | 0.76 ± 0.18                       |
| Pentadecanoic acid 15:0, % | 0.22 ± 0.05                       |
| Palmitic acid 16:0, % | 10.88 ± 0.63                       |
| Palmitoleic acid 16:1n–7, % | 2.56 (1.01)                       |
| Stearic acid 18:0, % | 0.74 (0.15)                        |
| Oleic acid 18:1n–9, % | 22.25 ± 1.82                      |
| Linoleic acid 18:2n–6, % | 50.99 ± 3.66                      |
| γ-linolenic acid 18:3n–6, % | 0.82 ± 0.31                       |
| α-linolenic acid 18:3n–3, % | 1.02 ± 0.25                       |
| Dihomo-γ-linolenic acid 20:3n–6, % | 0.68 ± 0.18                       |
| Arachidononic acid 20:4n–6, % | 6.43 ± 1.2                        |
| EPA 20:5n–3, % | 1.59 (0.76)                         |
| DHA 22:6n–3, % | 0.75 ± 0.18                         |
| Stearoyl CoA desaturase-1 (SCD-1)⁴ | 0.23 (0.09)                       |
| Δ5 desaturase (D5D)⁵ | 9.42 (3.47)                        |
| Δ6 desaturase (D6D)⁶ | 0.02 ± 0.007                       |
| Dietary intake |                                          |
| Energy, kcal | 2243 (1128)                        |
| Fat, E%   | 34 ± 6                              |
| SFA, E%  | 14 ± 3                              |
| MUFA, E% | 12 (2)                              |
| PUFA, E% | 5 (2)                               |
| Carbohydrate, E% | 42 ± 7                             |
| Protein, E% | 18 ± 3                             |
| Alcohol, E% | 3 (3)                              |
| Vitamin E, mg | 11 (6)                             |
| Fiber, g  | 28 (15)                             |

¹Data are presented as mean ± SD, %, or as median (IQR) for skewed distributed variables.
²BF, body fat; FFM, fat-free mass; NAFLD, nonalcoholic fatty liver disease; REE, resting energy expenditure; RQ, respiratory quotient; TG, triglycerides; VO₂max, maximal aerobic capacity; WC, waist circumference.
³Assessed by indirect calorimetry.
⁴Presented as the proportion of total fatty acids in serum cholesterol esters.
⁵Estimated as 16:1n–7/16:0.
⁶Estimated as 20:4n–6/20:3n–6.
⁷Estimated as 18:3n–6/18:2n–6.
bile ducts. Median fat content in the volume of interest was measured. A more detailed description of the MRI methodology and the quantification of liver fat concentrations has previously been presented (34). Prevalence of NAFLD was determined by a liver fat content exceeding 5.5%.

**Substrate utilization, REE, and maximal aerobic capacity**

To assess whole-body substrate utilization and energy metabolism, participants arrived at the laboratory in a fasted state (since midnight) between 09:00 and 10:00. While lying in a supine position, after 1 h of rest, pulmonary gas exchange of oxygen (VO2) and carbon dioxide (VCO2) were measured over a period of 30 min using a ventilated hood and the indirect calorimetry technique (Jaeger Oxycon Pro, Vyaire Medical). Whole-body RQ was calculated using the following formula: VCO2/VO2. An RQ value of 1 indicates pure carbohydrate oxidation whereas an RQ value of 0.7 indicates pure fat oxidation. For post hoc analyses, the whole-body basal fat oxidation rate was calculated using the equation developed by Frayn (35) and was normalized for FFM, as analyzed by bioelectrical impedance analysis (BIA) (Tanita BC-418). REE was calculated using the abbreviated Weir equation (36) and was also normalized for FFM.

A graded maximal exercise test, using a bicycle ergometer and pulmonary gas exchange (Jaeger Oxycon Pro, Vyaire Medical), was used to measure maximal aerobic capacity (VO2max). Participants were instructed to work until volitional exhaustion while the workload was increased by 10 W per minute, starting at 30 W for females and 50 W for males. Maximal heart rate, blood pressure, vital capacity, VCO2 and VO2 consumption were recorded.

**Dietary intake**

A self-administered semiquantitative FFQ consisting of 139 items (including alcohol) was completed by the participants to assess usual frequency of consumption over the past year. Nutrient composition was calculated using the Swedish Food Composition Database and age-specific portion sizes. Reported intakes of dietary fatty acids were presented as relative intakes (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat). A shorter version of the updated FFQ, consisting of 96 items has been validated against fatty acid (percent of total fat).

**Statistical analyses**

The primary analysis of this study was to investigate the associations between serum CE fatty acids and liver fat content. Secondary analyses included the associations between serum CE fatty acids and REE and RQ and whether these associations could explain potential links between serum CE fatty acids and liver fat content. Correlation analyses (Pearson) were performed between fatty acids in serum CEs (independent variables) and RQ, REE/FFM, and liver fat (dependent variables) as well as between RQ, REE/FFM (independent variables), and liver fat (dependent variable). Simple and multivariable linear regression analyses were performed between fatty acids in serum CEs and liver fat, adjusted for BMI and VO2max in model 1, model 1 + carbohydrate, fat, vitamin E, and alcohol intake in model 2, and model 2 + sex in model 3. For serum CE fatty acids that correlated with both liver fat and REE/FFM, additional multivariable linear regression analyses were performed with liver fat as the dependent variable and serum CE fatty acids as independent variables with REE/FFM included as a covariate in the adjusted model. Regression coefficients (β) with corresponding 95% CIs are reported for each linear regression model. Adjustment for multiple comparisons (n = 16 statistical hypothesis tests) was applied in post hoc analyses for the associations between fatty acids in serum CEs and liver fat, REE, and REE/FFM using the Benjamini–Hochberg procedure with a false discovery rate of 0.05. The distribution of the variables was examined statistically by the Shapiro–Wilk test and nonnormally distributed variables (W < 0.95) were logarithmically transformed. A variance inflation factor (VIF) >5 was used to indicate multicollinearity between included covariates. All statistical analyses were carried out using JMP software version 13.1.0 (SAS Institute, Inc.). A P value < 0.05 was set as the significance level. For post hoc analyses after adjustment for multiple comparisons, a P value < 0.02 was set as the significance level.

**Results**

Population characteristics are presented in Table 1. The study population (n = 308) did not differ from the full population cohort (n = 502) with regard to covariates in Table 1. The study population of middle-aged, equally distributed males (49%) and females (51%) was, despite moderate overweight (BMI of 25.8) and elevated serum cholesterol concentrations (total serum cholesterol of 5.3 mmol/L and LDL cholesterol of 3.4 mmol/L), generally regarded as healthy. The prevalence of NAFLD (22.7%) was not considered high nor low.

**Serum CE fatty acids and liver fat**

In serum CEs, linoleic acid (18:2n–6) (r = −0.28, P = <0.0001), DHA (22:6n–3) (r = −0.12, P = <0.05), pentadecan-10:0 (15:0) (r = −0.21, P = <0.001), and estimated D5D activity (r = −0.23, P = <0.0001) were inversely correlated with liver fat, whereas palmitoleic acid (16:1n–7) (r = 0.23, P = <0.0001), oleic acid (18:1n–9) (r = 0.13, P = <0.05), γ-linolenic acid (18:3n–6) (r = 0.34, P = <0.0001), dihomo-γ-linolenic acid (20:3n–6) (r = 0.41, P = <0.0001), arachidonic acid (20:4n–6) (r = 0.25, P = <0.0001), and estimated SCD-1 (r = 0.22, P = <0.0001) and D6D (r = 0.35, P = <0.0001) activities were positively correlated with liver fat (Figure 2). After adjusting for BMI and VO2max (model 1), dietary factors (model 2), and sex (model 3) in multivariable linear regression analyses, palmitoleic acid (β = 0.37, 95% CI: 0.04, 0.70), linoleic acid (β = −0.03, 95% CI: −0.06, −0.001), γ-linolenic acid (β = 0.59, 95% CI: 0.28, 0.90), dihomo-γ-linolenic acid (β = 1.20, 95% CI: 0.65, 1.75), arachidonic acid (β = 0.08, 95% CI: 0.002, 0.16), SCD-1 (β = 0.36, 95% CI: 0.02, 0.71), D5D (β = −0.42, 95% CI: −0.76, −0.08), and D6D (β = 25.63, 95% CI: 11.98, 39.28), remained associated with liver fat whereas oleic acid (β = 0.009, 95% CI: −0.05, 0.06) and DHA (β = −0.24, 95% CI: −0.75, 0.27) did not. In general, the strengths of the associations...
were similar across the 3 models for most of the fatty acids. The association for pentadecanoic acid was attenuated after adjusting for sex (β = −1.69, 95% CI: −3.75, 0.37) (model 3) (Table 2). No multicollinearity was observed between included covariates in the multivariable linear regression analyses. Of the serum CE fatty acids inversely associated with liver fat, end-quartile comparisons showed that the difference in liver fat was largest for linoleic acid (1.71%, 93% relative difference), followed by pentadecanoic acid (1.35%, 71% relative difference). For serum CE fatty acids positively associated with liver fat, end-quartile comparisons of dihomo-γ-linolenic acid showed the largest difference in liver fat (3.05%, 229% relative difference) (Supplemental Table 1).

Serum fatty acids in NEFA and liver fat

In post hoc analyses, serum NEFA palmitic acid (16:0) was positively correlated (r = 0.25, P = <0.0001) whereas linoleic acid was inversely correlated (r = −0.12, P = <0.05) with liver fat content; no other correlations were observed (Supplemental Figure 1). In addition, fatty acids in serum CEs and NEFA demonstrated small to moderate correlations with fatty acids derived from FFQs (Supplemental Figure 2). Lastly, minor differences in serum CE fatty acid proportions were observed between males and females (Supplemental Table 2).

Serum CE fatty acids and RQ

In serum CEs, only palmitoleic acid (r = −0.11, P = <0.05) and estimated SCD-1 activity (r = −0.10, P = <0.05) were weakly negatively correlated with RQ. However, no other fatty acids were correlated with RQ (Figure 2). Conversely, no correlation was observed between basal RQ and liver fat content (r = −0.03, P = 0.63).

Post hoc analyses using the calculated basal fat oxidation rate instead of RQ demonstrated similar, although somewhat stronger, correlations with serum CE fatty acids (Supplemental Table 3).

Serum CE fatty acids and REE

In serum CEs, palmitic acid (r = −0.12, P = <0.05), stearic acid (18:0) (r = −0.20, P = <0.0001), oleic acid (r = −0.14, P = <0.05), and dihomo-γ-linolenic acid (r = −0.17, P = <0.001) were negatively correlated with REE/FFM, whereas linoleic acid (r = 0.09, P = <0.05), DHA (r = 0.13, P = <0.05), and estimated D5D activity (r = 0.11, P = <0.05) were positively correlated with REE/FFM (Figure 2). In addition, REE/FFM was inversely correlated with liver fat content (r = −0.24, P < 0.0001).

In multivariable linear regression analyses of the fatty acids that were both associated with REE/FFM and liver fat content (Figure 2), oleic acid (β = 0.07, 95% CI: 0.01, 0.13), linoleic acid (β = −0.08, 95% CI: −0.11, −0.05), dihomo-γ-linolenic acid (β = 2.14, 95% CI: 1.57, 2.71), and D5D activity (β = −0.75, 95% CI: −1.13, −0.37), remained associated with liver fat also after adjusting for REE/FFM, whereas DHA did not (β = −0.34, 95% CI: −0.95, 0.27) (Table 3).
| Fatty Acid | Crude model | Model 1 | Model 2 | Model 3 |
|------------|-------------|---------|---------|---------|
|            | β (95% CI) | P value | β (95% CI) | P value | β (95% CI) | P value | β (95% CI) | P value |
| Myristic acid (14:0) | 0.45 (−0.17, 1.07) | 0.15 | −0.26 (−0.27, 0.79) | 0.33 | 0.13 (−0.41, 0.68) | 0.63 | 0.41 (−0.13, 0.95) | 0.14 |
| Pentadecanoic acid (15:0) | −4.29 (−6.59, −1.99) | 0.0003 | −2.56 (−4.51, −0.60) | 0.01 | −2.75 (−4.77, −0.74) | 0.008 | −1.69 (−3.75, 0.37) | 0.11 |
| Palmitic acid (16:0) | 0.17 (−0.005, 0.35) | 0.06 | −0.09 (−0.07, 0.24) | 0.27 | −0.09 (−0.07, 0.24) | 0.27 | 0.09 (−0.06, 0.24) | 0.24 |
| ln palmitoleic acid (16:1n–7) | 0.72 (0.38, 1.06) | <0.0001 | 0.32 (0.02, 0.62) | 0.04 | −0.29 (−0.04, 0.63) | 0.49 | 0.37 (0.04, 0.70) | 0.03 |
| ln stearic acid (18:0) | 0.57 (−0.06, 1.20) | 0.38 | 0.34 (−0.21, 0.88) | 0.23 | 0.38 (−0.17, 0.94) | 0.18 | 0.39 (−0.26, 0.83) | 0.30 |
| Oleic acid (18:1n–9) | −0.08 (−0.10, −0.05) | <0.0001 | −0.03 (−0.06, −0.01) | 0.02 | −0.03 (−0.06, −0.01) | 0.02 | −0.03 (−0.06, −0.01) | 0.04 |
| γ-linolenic acid (18:3n–6) | 1.10 (0.76, 1.45) | <0.0001 | 0.67 (0.37, 0.98) | <0.0001 | 0.64 (0.33, 0.96) | <0.0001 | 0.59 (0.28, 0.90) | 0.0002 |
| α-linolenic acid (18:3n–3) | 0.08 (−0.36, 0.52) | 0.73 | −0.004 (−0.38, 0.37) | 0.98 | −0.071 (−0.45, 0.32) | 0.73 | −0.04 (−0.42, 0.33) | 0.82 |
| Dihomo-γ-linolenic acid (20:3n–6) | 2.28 (1.72, 2.85) | <0.0001 | 1.23 (0.69, 1.77) | <0.0001 | 1.27 (0.71, 1.83) | <0.0001 | 1.20 (0.65, 1.75) | <0.0001 |
| Arachidonic acid (20:4n–6) | 0.21 (0.12, 0.30) | <0.0001 | 0.08 (0.003, 0.17) | 0.04 | 0.09 (0.01, 0.18) | 0.02 | 0.08 (0.002, 0.16) | 0.045 |
| ln EPA (20:5n–3) | 0.03 (−0.27, 0.33) | 0.84 | −0.08 (−0.33, 0.17) | 0.52 | −0.09 (−0.35, 0.17) | 0.49 | −0.06 (−0.31, 0.20) | 0.66 |
| DHA (22:6n–3) | −0.63 (−1.24, −0.02) | 0.04 | −0.43 (−0.94, 0.08) | 0.10 | −0.37 (−0.89, 0.16) | 0.17 | −0.24 (−0.75, 0.27) | 0.36 |
| ln stearoyl CoA desaturase-1 (SCD1) | 0.73 (0.37, 1.09) | <0.0001 | 0.32 (0.003, 0.64) | 0.04 | 0.28 (−0.07, 0.03) | 0.12 | 0.36 (0.02, 0.71) | 0.04 |
| ln Δ5 desaturase (DS5) | −0.81 (−1.19, −0.43) | <0.0001 | −0.46 (−0.79, −0.13) | 0.007 | −0.44 (−0.79, −0.09) | 0.01 | −0.42 (−0.76, −0.08) | 0.02 |
| Δ6 desaturase (D6D) | 49.48 (34.77, 64.20) | <0.0001 | 29.08 (15.72, 42.44) | <0.0001 | 28.17 (14.23, 42.12) | <0.0001 | 25.63 (11.98, 39.28) | 0.0003 |

1Data are presented as β, regression coefficient with 95% CI with corresponding P value.

D5D, Δ5 desaturase (20:4n–6/20:3n–6); D6D, Δ6 desaturase (18:3n–6/18:2n–6); SCD-1, stearoyl CoA desaturase-1 (16:1n–7/16:0); VO2max, maximal aerobic capacity.

2n = 284.

3n = 280.
magnetic resonance spectroscopy (1H-MRS) or indirectly via correlation between D6D and liver fat assessed directly by proton correlation between linoleic acid and liver fat and a positive association. The majority of these associations in the current study are in accordance with 2 other Swedish population-based studies, partly explained by methodological discrepancies between our study and the 2 other Swedish studies. Over a 10-y follow-up period, baseline serum alanine aminotransferase (ALT) (32, 39). Moreover, a positive association was observed for palmitoleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, and SCD-1 after adjusting for relevant covariates. A 1.71% absolute difference (93% in relative numbers) in liver fat was observed between the 4th and 1st quartile of linoleic acid proportion. Considering that NAFLD is diagnosed with a liver fat content of >5.5%, a 1.7% absolute difference is arguably a clinically relevant effect. Furthermore, a mean difference of 8.97% between end-quartile proportions of linoleic acid (data not shown) is in line with the trials discussed above showing a mean difference in change of linoleic acid in serum CEs of 5.8–6.5%, corresponding to a dietary linoleic acid intake of 12–14 E% (7, 8). Interestingly, we also found an inverse association between pentadecanoic acid, a biomarker of dairy fat intake (43) and liver fat content. Biomarkers of dairy fat intake have previously been associated with reduced liver fat in a smaller cross-sectional study (44) but interventional studies are needed to determine a possible causality behind such an association. However, oral supplementation with pentadecanoic acid in rabbits was recently shown to improve multiple liver health indices and attenuate fibrosis (45). Several serum CE fatty acids as well as D5D were significantly correlated with REE/FFM, although this relation had minor influence on the link between serum CE fatty acids and liver fat. However, DHA could potentially, to a certain extent, explain a lower liver fat content mediated through an increased REE/FFM as indicated in multivariable models. Furthermore, although palmitoleic acid and SCD-1 were significantly inversely correlated with RQ, indicating a higher basal fat oxidation rate, this could not, however, explain the association with a higher liver fat content since RQ itself was not correlated with liver fat. Interestingly, serum and/or plasma fatty acids that

### Adjustments for multiple comparisons (post hoc analyses)

After adjusting for multiple comparisons for the associations between serum fatty acids in CEs and liver fat, RQ, and REE/FFM, DHA was nonsignificantly inversely associated with liver fat in the crude model, whereas palmitoleic acid, linoleic acid, arachidonic acid, SCD-1, and D5D were nonsignificantly associated with liver fat in the full multivariable adjusted model. SCD-1 was nonsignificantly inversely associated with RQ whereas linoleic acid was nonsignificantly positively associated with REE/FFM. Since DHA was not associated with liver fat in these posthoc analyses, it was not included in further models adjusting for REE/FFM. In these latter models, oleic acid was nonsignificantly associated with liver fat. All other associations observed in the main analyses remained after adjusting for multiple comparisons (data not shown).

### Discussion

In this population-based sample of middle-aged individuals, the 2 PUFAs, linoleic acid and DHA, as well as pentadecanoic acid and D5D were inversely correlated with liver fat whereas palmitoleic acid, oleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, and SCD-1 and D6D were positively correlated with liver fat. The majority of these associations remained after full adjustments.

Associations between serum CE fatty acids and liver fat in the current study are in accordance with 2 other Swedish population-based studies, both of which observed a negative correlation between linoleic acid and liver fat and a positive correlation between D6D and liver fat assessed directly by proton magnetic resonance spectroscopy (1H-MRS) or indirectly via alanine aminotransferase (ALT) (32, 39). Moreover, a positive association was observed for palmitoleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, and SCD-1 after adjusting for relevant covariates in 1 study (39). However, some minor discrepancies were noticeable between our study and the 2 other Swedish population-based studies, partly explained by methodological differences in the assessment of liver fat and a lack of power due to a smaller sample size. Our findings also accord with a previous prospective cohort study using ultrasonography to diagnose steatosis (40). Over a 10-y follow-up period, baseline serum linoleic acid was inversely associated, whereas DHA was nonsignificantly inversely associated with the incidence of fatty liver.

**TABLE 3** Simple and multivariable linear regression analyses between fatty acids in serum cholesteryl esters and ln liver fat, adjusted for resting energy expenditure normalized for fat-free mass

| Fatty Acid                    | Crude model | Adjusted model | P value |
|------------------------------|-------------|----------------|---------|
| Oleic acid (18:1n–9)         | 0.07 (0.01, 0.13) | 0.07 (0.01, 0.13) | 0.03   |
| Linoleic acid (18:2n–6)      | −0.8 (−0.10, −0.05) | <0.0001 | <0.0001 |
| Dihomo-γ-linolenic acid (20:3n–6) | 2.28 (1.72, 2.85) | <0.0001 | 2.14 (1.57, 2.71) | <0.0001 |
| DHA (22:6n–3)                | −0.63 (−1.24, −0.02) | 0.04 | −0.34 (−0.95, 0.27) | 0.27 |
| ln Δ5 desaturase (D5D)       | −0.81 (−1.19, −0.43) | <0.0001 | −0.75 (−1.13, −0.37) | 0.0001 |

1Data are presented as β, regression coefficient with 95% CI with corresponding P value. Serum fatty acids in cholesteryl esters that correlated with both liver fat and resting energy expenditure normalized for fat-free mass were included in the crude and adjusted models.

2D5D, Δ5 desaturase (20:4n–6/20:3n–6).

n = 292.

Interestingly, observational studies on self-reported dietary intake in relation to liver fat show a positive correlation between SFA intake and liver fat and a trend towards a negative correlation with MUFA and PUFA intake (41). Conflicting findings have, however, been reported (5, 42). When dietary fatty acid classes were correlated with liver fat in our study, a weak inverse trend was observed for PUFAs (data not shown), partly explained by the weak to moderate correlations between dietary fatty acids and serum CE fatty acids (Supplemental Figure 2). Meanwhile, randomized controlled feeding trials conducted by our group and others point to a greater benefit of mainly consuming unsaturated fat (linoleic acid in particular) over SFA (palmitic acid in particular) in relation to liver fat accumulation (7–10). In accordance with these trials, linoleic acid in serum CEs was inversely associated with liver fat in the current study after adjusting for several covariates. A 1.71% absolute difference (93% in relative numbers) in liver fat was observed between the 4th and 1st quartile of linoleic acid proportion. Considering that NAFLD is diagnosed with a liver fat content of >5.5%, a 1.7% absolute difference is arguably a clinically relevant effect. Furthermore, a mean difference of 8.97% between end-quartile proportions of linoleic acid (data not shown) is in line with the trials discussed above showing a mean difference in change of linoleic acid in serum CEs of 5.8–6.5%, corresponding to a dietary linoleic acid intake of 12–14 E% (7, 8). Interestingly, we also found an inverse association between pentadecanoic acid, a biomarker of dairy fat intake (43) and liver fat content. Biomarkers of dairy fat intake have previously been associated with reduced liver fat in a smaller cross-sectional study (44) but interventional studies are needed to determine a possible causality behind such an association. However, oral supplementation with pentadecanoic acid in rabbits was recently shown to improve multiple liver health indices and attenuate fibrosis (45).
have been previously associated with increased cardiometabolic disease risk, showed inverse associations with REE/FFM, i.e. palmitic acid, stearic acid, oleic acid, and dihomo-γ-linolenic acid (46, 47).

Differences in postprandial- and 24-h fat oxidation rates between PUFAs, MUFAs, and SFAs have previously been observed in controlled feeding trials (11–14, 17, 48). However, trials that have assessed fat oxidation in the basal state have generally failed to detect a significant difference (16, 17, 19, 20). Although weak correlations between palmitoleic acid, SCD-1, and RQ were observed in our study, this could not explain lower liver fat. Furthermore, dietary unsaturated fatty acids can increase energy expenditure (22–24) and decrease ectopic fat in rodent models (22–25). Although human data are still conflicting (17, 19, 20, 26, 27, 48, 49), our results on serum CE fatty acids and REE are in line with above-mentioned rodent studies. Interestingly, when DHA and liver fat was adjusted for REE/FFM, the association was markedly attenuated, possibly indicating that DHA may influence liver fat through increased REE. In support of this finding, human supplementation trials of ω-3 as well as studies in rodents have shown increased energy expenditure and reduced liver fat (42, 50–52), possibly explained by a diet-induced increase in mitochondrial energy dissipation (53, 54). Further investigation on the relation between DHA, REE, and liver fat is, however, needed (54).

There are several strengths of this study, including the relatively large population-based sample, the inclusion of both males and females to increase generalizability, the use of objective fatty acid biomarkers instead of self-reported dietary intakes, the use of indirect calorimetry to assess energy metabolism, and the use of MRI to quantify liver fat. Thus, the simultaneous data on serum CE fatty acids, liver fat, and energy metabolism in a population-based setting must be regarded as unique and novel. In addition, several variables such as FFM using BIA and VO2max using a cycle ergometer were measured to make sure valid covariates were adjusted for, although residual confounding is inevitable. However, there are some limitations. The study used a cross-sectional design, which means that causal inferences cannot be drawn. In addition, the population sample consisted of individuals aged 50 y, which limits generalizability, but instead excludes age-related bias. Other limitations include the lack of information on the CV for the indirect calorimetry measurements as well as the lag time between the collection of blood samples and performance of MRI scans. Furthermore, the fatty acid composition is presented as raw area percentages; potential differential response factors for individual fatty acids could not be accounted for, which may introduce bias as split-injection was used. Finally, some caution is warranted when interpreting the data from the main analyses due to the lack of control for multiple testing, a statistical procedure that is albeit debated in explorative settings. However, additional post hoc analyses adjusting for multiple comparisons had minor to moderate influence on the results.

In conclusion, several serum CE fatty acids are associated with liver fat, among them linoleic acid. Although we identified novel associations between individual fatty acids and RQ and REE, our findings imply that PUFAs might prevent liver fat accumulation through mechanisms other than enhanced whole-body energy metabolism.

We would like to thank Lillemor Källström and Siv Tengblad for analyzing fatty acid composition, Gunilla Arvidsson, Anders Lundberg, and Gerd Nyman for collecting MRI data and Agneta Åkesson and Niclas Häkansson for quantifying FFQ data.

The authors’ contributions were as follows—UR, MF, FR, and LL: designed the research; JK and MF: conducted the research; HA, JK, and LL: provided databases; MF and JK: analyzed data; MF, FR, and UR: wrote the manuscript; UR: had primary responsibility for final content; and all authors: reviewed, revised, and approved the final manuscript. The authors report no conflicts of interest.

Data Availability

Data described in the manuscript will be made available from the corresponding author upon reasonable request.

References

1. Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther 2017;46(2):85–95.
2. Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018;41(2):372–82.
3. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016;65(3):589–600.
4. Hodson L, Rosqvist F, Parry SA. The influence of dietary fatty acids on liver fat content and metabolism. Proc Nutr Soc 2020;79(1):30–41.
5. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006;25(5):816–23.
6. Volynets V, Küper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, Königsrainer A, Bischoff SC, Bergheim I. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2012;57(7):1932–41.
7. Bjermo H, Iggnan D, Kullberg J, Dahlman I, Johansson L, Persson L, Berglund J, Pulkki K, Basu S, Usitupa M, et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr 2012;95(5):1003–12.
8. Rosqvist F, Iggnan D, Kullberg J, Cederkarea J, Johansson HE, Larsson A, Johansson L, Ahlström H, Arner P, Dahlman I, et al. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver fat and visceral fat accumulation in humans. Diabetes 2014;63(7):2356–68.
9. Luukkonen PK, Sädevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, Lallukka S, Pelloux V, Gaggini M, Jian C, et al. Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care 2018;41(8):1732–9.
10. Rosqvist F, Kullberg J, Stähmman I, Cederkarea J, Heurling K, Johansson HE, Iggnan D, Wilking H, Larsson A, Eriksson O, et al. Overeating saturated fat promotes fatty liver and ceramides compared to polyunsaturated fat: a randomized trial. The Journal of Clinical Endocrinology & Metabolism 2019;104(12):e2079–19.
11. Cenedella RJ, Allen A. Differences between the metabolism of linoleic and palmitic acid: utilization for synthesis and oxidation to respiratory CO2. Lipids 1969;4(2):155–8.
12. Leyton J, Drury PJ, Crawford MA. Differential oxidation of saturated and unsaturated fatty acids in vivo in the rat. Br J Nutr 1987;57(3):383–93.
13. DeLany JP, Windhauser MM, Champagne CM, Bray GA. Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr 2000;72(4):905–11.
14. Parry SA, Rosqvist F, Cornfield T, Barrett A, Hodson L. Oxidation of dietary linoleate occurs to a greater extent than dietary palmitate in vivo in humans. Clin Nutr 2021;40(3):1108–14.
15. Piers LS, Walker KZ, Stone RM, Soares MJ, O’Dea K. The influence of the type of dietary fat on postprandial fat oxidation
rates: monounsaturated (olive oil) vs saturated fat (cream). Int J Obes 2002;26(6):814–21.
16. Jones PJ, Schoeller DA. Polymunsaturated:saturated ratio of diet fat influences energy substrate utilization in the human. Metabolism 1988:37(2):145–51.
17. Kien CL, Bunn JY, Ugrasbul F. Increasing dietary palmitic acid decreases fat oxidation and daily energy expenditure. Am J Clin Nutr 2005;82(2):320–6.
18. Yajima K, Iwayama K, Ogata H, Park I, Tokuyama K. Meal rich in rapseed oil increases 24-h fat oxidation more than meal rich in palm oil. PLoS One 2018;13(6):e0189558.
19. Gillingham LG, Robinson KS, Jones PJ. Effect of high-oleic canola and flaxseed oils on energy expenditure and body composition in hypercholesterolemic subjects. Metabolism 2012;61(11):1598–605.
20. Piers LS, Walker KZ, Stoney RM, Soares MJ, O’Dea K. Substitution of saturated with monounsaturated fat in a 4-week diet affects body weight and composition of overweight and obese men. Br J Nutr 2003;90(3):717–27.
21. Clarke SD. Polysaturated fatty acid regulation of gene transcription: a mechanism to improve energy balance and insulin resistance. Br J Nutr 2000;83(S1):SS9–66.
22. Matsuo T, Takeuchi H, Suzuki H, Suzuki M. Body fat accumulation is greater in rats fed a beef tallow diet than in rats fed a safflower or soybean oil diet. Asia Pac J Clin Nutr 2002;11(4):302–8.
23. Mercer SW, Trayhurn P. Effect of high-fat diets on energy balance and thermogenesis in brown adipose tissue of lean and genetically obese ob/ob mice. J Nutr 1987;117(12):2147–53.
24. de Wit N, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshktar S, Duval C, de Vogel-van den Bosch J, Kleebergezem M, Müller M, van der Meer R. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012;303(5):G589–99.
25. Duivenvoorde LP, van Schothorst EM, Swarts HM, Kuda O, Steenbergh J, van Der Velden R, Verhees JL, van der Schouw YT, Brouns F. The effect of fat composition of the diet on energy metabolism. Zeitschrift für Ernährungswissenschaft 1997;36(4):303–5.
26. Kien CL, Bunn JY, Tompkins CL, Dumas JA, Crain KI, Ebenstein DB, Kopecky J, Keijer J. A difference in fatty acid composition of isocaloric high-fat diets alters metabolic flexibility in male C57BL/6J OlaHsd mice. PLoS One 2015;10(6):e0128515.
27. Van Marken Lichtenbelt WD, Mensink RP, Westerterp KR. The effect of fat composition of the diet on energy metabolism. Zeitschrift für Ernährungswissenschaft 1997;36(4):303–5.
28. Akriviadou AD, Karamanos PN, Pitsiou AM, Savvidou M, Tsagarakis G, Vlitos G, et al. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: a pooled analysis of prospective cohort studies. PLoS Med 2018;15(10):e1002670.
29. Krawczyk M, Szczepanik M, Galuszka K, Stęszewski P, Kozikowski P, Jaworski J, et al. Intake of saturated fat is associated with increased daily physical activity and resting energy expenditure and with changes in mood. Am J Clin Nutr 2013;97(4):689–97.
30. Huang X, Sjögren P, Cederholm T, Åmlov J, Lindholm B, Risérus U, Carrero JJ. Serum and adipose tissue fatty acid composition as biomarkers of habitual dietary fat intake in elderly men with chronic kidney disease. Nephrology Dialysis Transplantation 2014;29(1):128–36.
31. Wolk A, Furuheim M, Vessby B. Fatty acid composition of serum cholesteryl esters as quantitative biomarkers of dietary intake. Am J Clin Nutr 1988;37(2):145–51.
32. Lind L, Strand LM, Michaelsson K, Ahlström H, Kullberg J. Voxel-wise study of cohort associations in whole-body MRI: application in metabolic syndrome and its components. Radiology 2020;294(3):559–67.
33. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol Respir Environ Exerc Physiol 1983;55(2):628–34.
34. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949;109(1–2):1–9.
35. Wallin A, Di Giuseppe D, Burgaz A, Håkansson N, Cederholm T, Michaelsson K, Wolk A. Validity of food frequency questionnaire-based estimates of long-term long-chain n-3 polysaturated fatty acid intake. Eur J Nutr 2014;53(2):549–55.
36. Levitan EB, Westgren CW, Liu S, Wolk A. Reproducibility and validity of dietary glycemic index, dietary glycemic load, and total carbohydrate intake in 141 Swedish men. Am J Clin Nutr 2007;85(2):548–53.
37. Petersson H, Amlöv J, Zethelius B, Risérus U. Serum fatty acid composition and insulin resistance are independently associated with liver fat markers in elderly men. Diabetes Res Clin Pract 2010;87(3):379–84.
38. Kaikkonen JE, Würtz P, Suomela E, Lehtovirta M, Kangas AJ, Jula A, Mikkilä V, Viikari JS, Juonala M, Rönnuma T, et al. Metabolic profiling of fatty liver in young and middle-aged adults: cross-sectional and prospective analyses of the Young Finns Study. Hepatology 2017;65(2):491–500.
39. Cheng Y, Zhang K, Chen Y, Li Y, Li Y, Fu K, Feng R. Associations between dietary nutrient intakes and hepatic lipid contents in NAFLD patients quantified by 1H-MRS and dual-echo MRS. Nutrients 2016;8(9):579.
40. Oddy WH, Herbison CE, Jacoby P, Ambrosini GL, O’Sullivan TA, Amons M, et al. The Western dietary pattern is prospectively associated with non-alcoholic fatty liver disease in adolescence. Am J Gastroenterol 2013;108(5):778–85.
41. Imamura F, Fretts A, Marklund M, Ardisson Korat AV, Yang WS, Lankinen M, Qureshi W, Helmer C, Chen TA, Wong K, et al. Fatty acid biomarkers of dietary fat consumption and incidence of type 2 diabetes: a pooled analysis of prospective cohort studies. PLoS Med 2015;12(10):e1002067.
42. Kutz M, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Callahan HS, Song X, Di C, Ugrasbul F. Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not β-cell function in humans. Am J Clin Nutr 2014;99(6):1385–96.
43. Venn-Watson S, Lumphkin R, Dennis EA. Efficacy of dietary odd-chain saturated fatty acid pentadecenoic acid parabols broad associated health benefits in humans: could it be essential? Sci Rep 2020;10(1):8161.
44. Imamura F, Fretts AM, Marklund M, Korat Ardisson AV, Yang WS, Lankinen M, Qureshi W, Helmer C, Chen TA, Virtanen JK, et al. Fatty acids in the de novo lipogenesis pathway and incidence of type 2 diabetes: a pooled analysis of prospective cohort studies. PLoS Med 2020;17(6):e1003102.
45. Schulze MB, Minihane AM, Saleh RMN, Risérus U. Intake and metabolism of omega-3 and omega-6 fatty acids: nutritional implications for cardiometabolic diseases. The Lancet Diabetes & Endocrinology 2020;8(11):915–30.
46. Polley KR, Miller MK, Johnson M, Vaughan R, Paton CM, Cooper JA. Metabolic responses to high-fat diets rich in MUFAs v. PUFA. Br J Nutr 2018;120(1):13–22.
47. Kiel CL, Bunn JY, Tompkins CL, Dumas JA, Crain KI, Ebenstein DB, Kopecky J, Keijer J. A difference in fatty acid composition of isocaloric high-fat diets alters metabolic flexibility in male C57BL/6J OlaHsd mice. PLoS One 2015;10(6):e0128515.
48. Polley KR, Miller MK, Johnson M, Vaughan R, Paton CM, Cooper JA. Metabolic responses to high-fat diets rich in MUFAs v. PUFA. Br J Nutr 2018;120(1):13–22.
49. Mintz A, Helt B, Raben A, Toubro S, Astrup A. Effects of different dietary fat types on postprandial appetite and energy expenditure. Obes Res 2003;11(12):1449–55.
50. Logan SL, Spreit LL. Omega-3 fatty acid supplementation for 12 weeks increases resting and exercise metabolic rate in healthy community-dwelling older females. PLoS One 2015;10(12):e0144828.
51. Yan JH, Guan BJ, Gao HY, Peng XE. Omega-3 polysaturated fatty acid supplementation and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018;97(37):e12271.
52. Ferramosa A, Conta A, Burri L, Berge K, De Nuccio F, Guidetti AM, Zara V. A krill oil supplemented diet suppresses hepatic steatosis in high-fat fed rats. PLoS One 2012;7(6):e38797.
53. Kim M, Goto T, Yu R, Uchida K, Tominaga M, Kano Y, Takahashi N, Kawata H. Fish oil intake reduces UCPII in brown and white adipose tissue via the sympathetic nervous system. Sci Rep 2016;6(1):18013.
54. Lund J, Larsen LH, Laurizen L. Fish oil as a potential activator of brown and beige fat thermogenesis. Adipocyte 2018;7(2):88–95.